Promising drug against non-alcoholic steatohepatitis, a severe type of liver disease

by Fundació Bosch i Gimpera

4 years ago
drug, fatty liver disease, plasma, NASH, non-alcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) affects 2 to 5 percent of the world’s population. It is the most severe form of fatty liver disease, which can lead to cirrhosis, among other complications, and i...

The stabilization of new lipid mediators derived from omega-3 fatty acids reduces the liver inflammation caused by obesity

by Fundació Clínic per a la Recerca Biomèdica

9 years ago
non-alcoholic steatohepatitis, fatty liver disease

Inhibitors of sEH are suggested as a promising therapeutic strategy to prevent and counteract the consequences of obesity. Based on the significant results obtained in this work new studies will be la...